News

Collaboration aims to generate new drug candidates for neglected tropical diseases across the globe.

FDA-approved drugs or experimental drugs with ample health data could be rapidly tested in humans for treatment of COVID-19.

The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.

A small molecule that activates the immune protein STING shows promising results against tumors.

An international research network centers around ReFRAME, the world’s leading collection of drugs known to be safe in humans.

Calibr scientists work to repurpose existing drugs against novel coronavirus.

Having achieved this regulatory milestone, Calibr can begin clinical trials for its novel cell therapy candidate, which leverages a patient's own immune cells to treat cancer.

Renewed support from the Bill & Melinda Gates Foundation to accelerate research by Calibr, the drug development division of Scripps Research.

Under a two-year contract and funding agreement, Calibr will screen its vast library of drug molecules for compounds that work against a rare but vexing family of bacteria.

This video by Boston Globe’s STAT magazine features Calibr’s ReFRAME collection, a drug repurposing project that’s finding ways to treat new diseases with existing drugs.

Calibr scientists build and deploy new ReFRAME drug collection to find potential therapies against HIV, tuberculosis and parasites that causes severe illness in children.

Scripps Research is Science Changing Life

The researchers estimated that a single human dose of the drugs would convey an insecticide effect against mosquitos and sand flies lasting 50–90 days.

The research offers another approach for tackling diseases that have been considered “undruggable,” including ALS, muscular dystrophy, cystic fibrosis and certain cancers.

Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors.

Scientists at Calibr and Scripps Research have discovered how a potential new drug targets this deadly disease.

Calibr has now identified and repurposed an FDA-approved drug, clofazimine, used for decades to treat leprosy, as a potential new treatment for cryptosporidiosis.

Known as KA34, the drug is a small molecule that “encourages adult stem cells already residing in the joint to mature toward chondrocytes, the cells that produce and maintain healthy cartilage..."

World-class research institute and new innovation center partner to accelerate early translational research.

Leaders in basic and translational research at TSRI and Calibr will provide target materials and relevant know‐how to prosecute drug targets of interest.